Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03749629 · ClinicalTrials.gov registry record · NA
Comparative Effectiveness of Pharmacogenomics for Treatment of Depression
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 201
- Enrollment target
NCT03749629: Completed NA study, sponsored by Massachusetts General Hospital.
NCT03749629 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 201 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03749629, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 201 participants
- Enrollment target
Study Summary
The overall goal of this study is to assess the effectiveness of a widely available and widely used combinatorial pharmacogenomic (PGx) test for the treatment of major depressive disorder. Pharmacogenomic tests use genetic information to guide medication treatment decisions. The tests inform clinicians and patients of potential gene-drug interactions by analyzing pharmacokinetic (PK) genes (how drugs are metabolized) as well as pharmacodynamic (PD) genes (how drugs work). While combinatorial PGx testing is attractive to clinicians, patients, healthcare systems, and insurers, limited data demonstrate that PGx testing will result in better outcomes compared to evidence-based guideline treatment. Therefore, the investigators will conduct a prospective randomized comparative effectiveness study of best practice guidelines plus combinatorial PGx-guided treatment versus best-practice guideline concordant treatment alone.
Primary Outcome
Hypothesis: Combinatorial PGx-guided treatment will be superior to best-practice guideline treatment to increase well-being The World Health Organization-5 Well-Being Index (WHO-5, primary outcome measure) is a brief 5-item self-report questionnaire consisting of positively-worded statements related to positive mood, vitality, and general interests over the prior two weeks. Item scores range from 0 (none of the time) to 5 (all of the time), resulting in a range of summary scores from 0 (poor wel
Interventions
- OTHER GeneSight Psychotropic test
- OTHER Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2022-03-15 |
| Phase | NA |
What the finished NCT03749629 record still lists
NCT03749629 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 2 interventions - of which GeneSight Psychotropic test is the first listed.
NCT03749629 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03749629 about?
NCT03749629 is a clinical study titled "Comparative Effectiveness of Pharmacogenomics for Treatment of Depression". The overall goal of this study is to assess the effectiveness of a widely available and widely used combinatorial pharmacogenomic (PGx) test for the treatment of major depressive disorder. Pharmacogenomic tests use genetic information to guide medication treatment decisions. The tests inform clinici...
What is the current status of trial NCT03749629?
This trial is currently completed. It is a NA study. The enrollment target is 201 participants. The study started on 2019-05-01. Estimated completion is 2022-03-15.
What interventions are being tested in trial NCT03749629?
The interventions under investigation include: GeneSight Psychotropic test (OTHER), Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines (OTHER).
Who is sponsoring clinical trial NCT03749629?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03749629's enrollment target sits among peer trials
201 506th of 2000 higher than 1,495 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI